Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet GLP 1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review ScienceDirect 5 GLP 1 trends to expect in 2026: Expanded uses, oral options, and more AOL Three new #GLP 1 drugs for obesity treatment2 injectables and 1 pillmay receive FDA approval this year. Here's how high dose semaglutide, cagrilintide plus semaglutide, and orforglipron performed in phase 3 trials.